Selexis Announces Expansion of R&D License Agreement with Amgen

       Selexis Announces Expansion of R&D License Agreement with Amgen

Expansion to Include the Selexis SURE CHO-M Cell Line™

PR Newswire

GENEVA, Feb. 20, 2013

GENEVA, Feb. 20, 2013 /PRNewswire/ --Selexis SA, a global life sciences
company for drug discovery, cell line development and scale-up to
manufacturing of therapeutic proteins, announced today that Amgen has expanded
their R&D License Agreement with Selexis to include an evaluation of the
proprietary Selexis SURE CHO-M Cell Line™ for research and development. Under
the agreement, Amgen will be able to evaluate the SURE CHO-M Cell Line™ in
conjunction with the Selexis SUREtech Vectors™ for improved R&D.

(Logo: http://photos.prnewswire.com/prnh/20120627/LA31604LOGO)

"Successful protein expression in R&D is dependent upon a cell line
development platform that is robust, high-yielding and stable," said Igor
Fisch, Ph.D., President and CEO of Selexis. "Selexis is continually optimizing
its proprietary cell line and technology platform to enable partners such as
Amgen to make better R&D decisions by generating reliable data points faster
and more cost efficiently. This current agreement is built on the
long-standing relationship between our two companies since 2004."

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a global life science
company with innovative technologies and world-class expert services for drug
discovery, cell line development and scale-up to manufacturing of therapeutic
proteins. The Company's SUREtechnology Platform™ is based on Selexis Genetic
Elements™ — novel DNA-based elements that control the dynamic organization of
chromatin within all mammalian cells and allow for higher and more stable
expression of recombinant proteins. Selexis has generated over 1,700 cell
lines being used in a variety of programs from drug discovery to late-stage
clinical trials.

For more information, visit http://www.selexis.com

Media Inquires
Robert Meister
Selexis SA
Tel: +1 (602) 953-1716
Email: robert.meister@selexis.com



SOURCE Selexis SA

Website: http://www.selexis.com